Logo image of NHWK

NIGHTHAWK BIOSCIENCES INC (NHWK) Stock Fundamental Analysis

NYSEARCA:NHWK - NYSE Arca - US42237K4094 - Common Stock - Currency: USD

0.4135  +0.03 (+8.96%)

After market: 0.4299 +0.02 (+3.97%)

Fundamental Rating

2

Taking everything into account, NHWK scores 2 out of 10 in our fundamental rating. NHWK was compared to 560 industry peers in the Biotechnology industry. Both the profitability and financial health of NHWK have multiple concerns. NHWK is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NHWK has reported negative net income.
In the past year NHWK has reported a negative cash flow from operations.
NHWK had negative earnings in each of the past 5 years.
In the past 5 years NHWK always reported negative operating cash flow.
NHWK Yearly Net Income VS EBIT VS OCF VS FCFNHWK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -74.32%, NHWK is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
NHWK has a worse Return On Equity (-143.11%) than 65.82% of its industry peers.
Industry RankSector Rank
ROA -74.32%
ROE -143.11%
ROIC N/A
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
NHWK Yearly ROA, ROE, ROICNHWK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

With a decent Gross Margin value of 28.70%, NHWK is doing good in the industry, outperforming 76.43% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for NHWK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NHWK Yearly Profit, Operating, Gross MarginsNHWK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

NHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NHWK has been increased compared to 1 year ago.
Compared to 1 year ago, NHWK has a worse debt to assets ratio.
NHWK Yearly Shares OutstandingNHWK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
NHWK Yearly Total Debt VS Total AssetsNHWK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

NHWK has an Altman-Z score of -6.72. This is a bad value and indicates that NHWK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.72, NHWK is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.25 indicates that NHWK is not too dependend on debt financing.
NHWK has a worse Debt to Equity ratio (0.25) than 71.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z -6.72
ROIC/WACCN/A
WACC10.89%
NHWK Yearly LT Debt VS Equity VS FCFNHWK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.99 indicates that NHWK may have some problems paying its short term obligations.
The Current ratio of NHWK (0.99) is worse than 90.40% of its industry peers.
NHWK has a Quick Ratio of 0.99. This is a bad value and indicates that NHWK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.99, NHWK is not doing good in the industry: 89.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.99
NHWK Yearly Current Assets VS Current LiabilitesNHWK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for NHWK have decreased strongly by -21.47% in the last year.
NHWK shows a strong growth in Revenue. In the last year, the Revenue has grown by 147.78%.
NHWK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.23% yearly.
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%

3.2 Future

NHWK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.45% yearly.
NHWK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 71.98% yearly.
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NHWK Yearly Revenue VS EstimatesNHWK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
NHWK Yearly EPS VS EstimatesNHWK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NHWK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NHWK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NHWK Price Earnings VS Forward Price EarningsNHWK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NHWK Per share dataNHWK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

NHWK's earnings are expected to grow with 18.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.97%
EPS Next 3Y18.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NHWK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NIGHTHAWK BIOSCIENCES INC

NYSEARCA:NHWK (2/5/2024, 8:04:02 PM)

After market: 0.4299 +0.02 (+3.97%)

0.4135

+0.03 (+8.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2023-11-20/amc
Earnings (Next)03-29 2024-03-29/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap36.34M
Analysts43.33
Price Target10.2 (2366.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.76%
Min EPS beat(2)-40.06%
Max EPS beat(2)-15.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-55.88%
Max Revenue beat(2)26.87%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.3
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.32%
ROE -143.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.7%
FCFM N/A
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.83%
Cap/Sales 121.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.99
Altman-Z -6.72
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)351.08%
Cap/Depr(5y)283.29%
Cap/Sales(3y)138.98%
Cap/Sales(5y)87.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
EBIT growth 1Y-45.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.4%
OCF growth 3YN/A
OCF growth 5YN/A